Clinical Trial Detail

NCT ID NCT02823405
Title Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors X4 Pharmaceuticals
Indications

melanoma

Therapies

Pembrolizumab + X4P-001

Age Groups: senior adult

No variant requirements are available.